The latest news from the AHA Scientific Sessions, with physician perspective, researcher interviews and clinician insight on cardiovascular prevention and more.
CHICAGO — Two-year data from the BASKET-PROVE II trial demonstrated that biolimus-eluting biodegradable polymer stents were noninferior to durable polymer everolimus-eluting stents in a real-world population of patients with large vessels. The biodegradable stent also was superior to a thin-strut bare-metal stent in this patient population.
CHICAGO — New data on evolocumab presented at the American Heart Association Scientific Sessions yielded positive data for the lipid-lowering and safety profiles of the PCSK9 inhibitor.
CHICAGO — Rivaroxaban was associated with significantly fewer total hospitalization days, fewer outpatient visits and fewer atrial fibrillation-related hospitalizations, according to an analysis presented at the American Heart Association Scientific Sessions.
CHICAGO — A novel bioabsorbable polymer-coated everolimus-eluting stent was noninferior to a durable polymer everolimus-eluting stent at 1 year, according to results from the EVOLVE II pivotal trial presented at the American Heart Association Scientific Sessions.
CHICAGO — New data from the phase 2 PreSERVE-AMI study suggest a dose-dependent benefit of autologous CD34+ cell therapy for patients with left ventricular dysfunction after STEMI.
CHICAGO — Young men with high trans-fat consumption had poorer scores on a memory test compared with men who had lower intake, according to a report presented at the American Heart Association Scientific Sessions.
CHICAGO — Results of several studies from the ODYSSEY program presented at the American Heart Association Scientific Sessions indicate that the investigational PCSK9 inhibitor alirocumab continues to show LDL-lowering efficacy in a variety of patient populations.
CHICAGO — A structured physical activity program had no effect on CV events in older adults compared with a health education program, according to new data from the LIFE study.
CHICAGO — At 20 years, men assigned statin therapy during the 5-year West of Scotland Coronary Prevention Study had lower rates for mortality and CV events compared with men assigned placebo, regardless of whether they continued taking statins, according to findings presented at the American Heart Association Scientific Sessions.
